Join to View Full Profile
3815 E Bell RdSte 1210Phoenix, AZ 85032
Phone+1 602-493-6626
Fax+1 602-996-1383
Dr. Lamm is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Univ. Calif. San Diego1972 - 1976
UCLA-VA Greater Los AngelesResidency, Surgery, 1971 - 1972
Oregon Health Science University HospitalInternship, Transitional Year, 1968 - 1969- Oregon Health & Science University1969
David Geffen School of Medicine at UCLAClass of 1968
Certifications & Licensure
CA State Medical License 1969 - Present
AZ State Medical License 2001 - 2024
WV State Medical License 1986 - 2002
TX State Medical License 1976 - 1987
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2016
- Super Doctor SuperDoctors.com
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Paclitaxel in Treating Patients With Early-Stage Bladder Cancer Start of enrollment: 1996 Nov 01
- Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Start of enrollment: 2008 Jan 01
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Start of enrollment: 2014 Mar 01
Publications & Presentations
PubMed
- 40 citationsBladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Se...Roger Li, Patrick J Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk
European Urology. 2024-12-01 - 49 citationsOncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01 - 1 citationsAuthor Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01
Journal Articles
- Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer.Colombel M, Soloway M, Akaza H, Bohle A, Palou J, Buckley R, Lamm DL, Brausi M, Witjes JA, Persad R, Eur Urol sup. 7: 618–626
- The potential application of Allium sativum (garlic) for the treatment of bladder cancer.Lamm DL and Riggs DR, Urol Clin North Am 27(1): 157-162
- Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncol...Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, and Crawford ED, J Urol 163(4): 1124-1129
Press Mentions
A New Love Affair — but Will You Respect Me in the Morning?July 25th, 2019
NanOlogy Announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder CancerApril 9th, 2019- Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder CancerMarch 12th, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
